BioBrief covers a selective biotech session driven by regulatory execution, rare-disease filings, and continued investor interest in differentiated clinical-stage stories.

In today’s BioBrief:

• Kyverna / miv-cel — Kyverna continued to rally after initiating a rolling BLA submission for miv-cel in stiff person syndrome, a potential milestone for autoimmune CAR-T therapy beyond oncology.
• BridgeBio / encaleret — BridgeBio’s encaleret NDA in autosomal dominant hypocalcemia type 1 remained in focus after Phase 3 CALIBRATE data showed strong calcium-normalization results versus standard therapy.
• Agios / mitapivat — Agios advanced mitapivat through an sNDA seeking accelerated approval in sickle cell disease, with FDA alignment on the confirmatory trial design.
•  ...